Abstract: The invention relates to use of compositions in therapeutics containing a compound having general formula (I): Wherein R, R1, R2, X and n are as described herein.
Type:
Application
Filed:
October 5, 2009
Publication date:
January 28, 2010
Applicant:
SANOFI-AVENTIS
Inventors:
Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Pascale MAGAT, Benoit MARABOUT, Pierre ROGER
Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and andolast, processes for preparing them and their use in the treatment of respiratory diseases.
Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the ?7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
Type:
Application
Filed:
August 31, 2009
Publication date:
January 21, 2010
Inventors:
Truc Minh Nguyen, Wenge Xie, Richard Schumacher, Brian Herbert, Ashok Tehim
Abstract: The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors.
Abstract: Disclosed are new quinine sulfate/bisulfate solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.
Type:
Application
Filed:
June 25, 2009
Publication date:
December 31, 2009
Inventors:
Tong Sun, Shawn Watson, Wei Lai, Stephan D. Parent
Abstract: A method of identification of quinoline compounds (formula I) that modify melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to control (e.g., inhibit) melanin production are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, pigmentation deficiencies (albinism) and hyperpigmentation and others.
Abstract: Provided herein are 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity. These compounds are useful for the treatment of diseases associated with CCR3 activity, including but not limited to, atopic dermatitis, allergic rhinitis, rheumatoid arthritis, Grave's disease, HIV infection, Alzheimer's disease, atherosclerosis and other inflammatory and/or immunological disorders.
Type:
Application
Filed:
July 16, 2009
Publication date:
November 19, 2009
Inventors:
Yingfu Li, Kevin Bacon, Hiromi Sugimoto, Keiko Fukushima, Kentaro Hashimoto, Makiko Marumo, Toshiya Moriwaki, Noriko Nunami, Naoki Tsuno, Klaus Urbahns, Nagahiro Yoshida
Abstract: The invention relates to compositions comprising a compound having general formula (I): Wherein R, R1, R2, X and n are as described herein. Also disclosed and claimed in certain of the embodiments herein are the methods of preparation of compound of formula (I) and its use in therapeutics.
Type:
Grant
Filed:
September 20, 2007
Date of Patent:
November 17, 2009
Assignee:
Sanofi-Aventis
Inventors:
Gihad Dargazanli, Genevieve Estenne-Bouhtou, Pascale Magat, Benoit Marabout, Pierre Roger
Abstract: The invention relates to adjunctive and simultaneous combination therapies for the treatment of psychotic disorders in which sabcomeline or a pharmaceutically acceptable salt thereof and at least one other neuroleptic agent are administered adjunctively or simultaneously. The invention provides methods of treatment of psychotic disorders utilising such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them.
Type:
Application
Filed:
July 16, 2009
Publication date:
November 12, 2009
Inventors:
Carol ROUTLEDGE, James Joseph Hagan, Stuart Paul Cuffe
Abstract: Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R1, R2 and R3 represent hydrogen, etc., X1 represents C1-6 alkylene, etc., X2 represents C1-6 alkylene, etc., A1 represents a 5- to 6-membered heterocyclic group, etc., and A2 represents C6-14 aryl, etc.
Abstract: A combination drug therapy can be administered to patients to treat xerostomia or dry mouth or Sjogren's syndrome in the form of orally dissolving film or orally disintegrating tablets. Some of the drugs could be synthetic origin and some drugs are obtained from natural sources.
Abstract: The invention provides a combination comprising an ancillary compound and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C?O, NR9(C?O) or 0(C?O) wherein R9 is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen, hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy; or a C1-4 hydrocarbyl group optionally substituted by
Type:
Application
Filed:
July 13, 2007
Publication date:
October 22, 2009
Applicant:
Astex Therapeutics Limited
Inventors:
John Francis Lyons, Matthew Simon Squires, Neil Thomas Thompson, Neil James Gallagher, Jayne Elizabeth Curry
Abstract: A novel polymorphic crystal form of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide, designated crystal form Talpha. Methods for preparing same and the use of the crystal form as the active ingredient of medicaments for the treatment of inflammatory or obstructive airways diseases are also described.
Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
Type:
Application
Filed:
June 29, 2009
Publication date:
October 15, 2009
Applicant:
Bayer Healthcare AG
Inventors:
Joachim Luithle, Frank-Gerhard Bob, Christina Erb, Katrin Schnitzler, Timo Flessner, Marja Van Kampen, Christoph Methfessel
Abstract: The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Type:
Application
Filed:
May 27, 2009
Publication date:
September 24, 2009
Applicant:
ACADIA PHARMACEUTICALS, INC.
Inventors:
Niels Skjaerback, Kristian Norup Koch, Bo Lennart Mikael Friberg, Bo-Ragnar Tolf
Abstract: The present invention provides a combination of: a N-containing drug molecule salt, wherein said drug molecule is selected from the group consisting of quinine and quinidine, and an aromatic mono- or dicarboxylic acid salt, e.g. quinine pamoate, which is useful for a pharmaceutical formulation such as a pediatric suspension, especially in the treatment of malaria.
Abstract: Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed are methods of using quinine and informing a user of information, including potential adverse effects, the effect of food on quinine's pharmacokinetics, effect of dosing various strengths of quinine, effect of maximum plasma concentrations of quinine in a patient as it relates to adverse events, effects of deviating from the prescribed dosage, etc.
Abstract: The present application describes deuterium-enriched palonosetron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: Compounds of formulae I and II: are disclosed as 5-HT3 inhibitors. Those compounds are useful in treating CINV, IBS-D and other diseases and conditions.
Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the ?7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
Abstract: Pharmaceutical formulation in the form of inhalable dry powder comprising particles of a pharmaceutically acceptable salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane as active ingredient, and particles of a carrier made of a physiologically acceptable pharmacologically-inert material are effective for the prevention and/or treatment of a respiratory disease such as asthma and COPD.
Abstract: The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.
Type:
Application
Filed:
November 17, 2008
Publication date:
July 30, 2009
Inventors:
Shawn Maddaford, Jailall Ramnauth, Suman Rakhit, Joanne Patman, Paul Renton, Subhash C. Annedi, John S. Andrews, Gabriela Mladenova
Abstract: This invention encompasses nicotinic acetylcholine receptor reactive compounds in accord with formula (I) Wherein: D represents O; E represents CH2, NH, O or S; n is 1 or 2 and stereoisomers, enantiomers, in vivo-hydrolysable precursors and pharmaceutically-acceptable salts of such compounds, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.
Abstract: Methods of modulating platelet procoagulant response are taught herein. Inhibition of platelet procoagulant response with agents that inhibit the Ca2+-sensitive K+ channels, or Gardos channels, preferably while maintaining platelet bleeding arrest function, may be used to treat a variety of disorders.
Abstract: Compositions which comprise a combination of a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane, and a long-acting phenylalkylamino beta2-agonist are effective for the prevention and treatment of inflammatory or obstructive airways diseases.
Abstract: A combination which comprises (a) a ?2 agonist and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.
Type:
Application
Filed:
March 17, 2009
Publication date:
July 9, 2009
Inventors:
Jordi Gras Escardo, Jesus Llenas Calvo, Hamish Ryder, Pio Orviz Diaz
Abstract: The invention relates to compositions comprising benzimidazolone derivatives of formula (I), optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof and methods of treating or preventing urinary incontinence, comprising the administration of a therapeutically effective amount of compound of formula (I), wherein R1, R2, R3, and R4 denote hydrogen or hydroxy with the proviso that R1, R2, R3, and R4 cannot simultaneously represent hydrogen, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof.
Type:
Application
Filed:
February 16, 2007
Publication date:
July 9, 2009
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
Type:
Grant
Filed:
March 3, 2003
Date of Patent:
June 30, 2009
Assignee:
Bayer Healthcare AG
Inventors:
Joachim Luithle, Frank-Gerhard Böβ, Christina Erb, Katrin Schnizler, Timo Fleβner, Marja van Kampen, Christoph Methfessel
Abstract: Compounds of formulae I and II: are disclosed as 5-HT3 inhibitors. Those compounds are useful in treating CINV, IBS-D and other diseases and conditions.
Abstract: The invention relates to the quinuclidine compounds of formula I having quaternary ammonium group, its preparation, and the pharmaceutical composition comprising an effective amount of the compound of formula I. The compound and the composition are used to prevent and treat the diseases by blocking acetylcholine receptor. Wherein: R1 is selected from C1-12 saturated straight-chain alkyl and cycloalkyl; R2 is selected from C1-12 saturated straight-chain allyl or straight-chain allyl; and X is selected from halogen ion, organic and inorganic acid radical.
Abstract: There is provided an agent comprising solifenacin succinate in an amount of 5 mg to 10 mg or solifenacin or a pharmaceutically acceptable salt thereof in an amount equimolar to 5 mg to 10 mg of solifenacin succinate for improvement of urinary urgency, pollakiuria and urinary incontinence due to neurogenic bladder caused by neurodegenerative diseases such as cerebrovascular disease or cerebral infarction, brain or spinal cord injury due to trauma, multiple sclerosis, Parkinson's disease, congenital malformation of the nerve system, peripheral neuropathy, and various spine lesions, that is, spinal cord compression and injury due to fracture, cervical and lumbar spondylosis, spondylosis deformans, spondylolisthesis, spinal stenosis, vertebral disk hernia and the like.
Abstract: Compounds of formula (I) are inhibitors of PDK1 and CHK1 activity, and of use in the treatment of cancer and autoimmune disorders (I): wherein R2 is a radical of formula R7—(CH2)n?, or a radical of formula -Alk-N(—R5)—R9 wherein n is 0, 1, 2 or 3 and Alk is C1-C6 alkylene; R7 is (i) a heterocyclic ring of 5 or 6 ring atoms coupled via a ring carbon wherein the sole heteroatom is nitrogen, optionally substituted by C1-C6 alkyl or aryl C1-C6 alkyl, (ii) 1-aza-bicyclo[2.2.2]oct-3-yl, or (iii) 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl; R8 and R9 are independently selected from hydrogen or C1-C3 alkyl; and the remaining substituents are as defined in the claims.
Type:
Application
Filed:
June 6, 2006
Publication date:
May 21, 2009
Applicant:
VERNALIS R & D LIMITED
Inventors:
David Lee Walmsley, Martin James Drysdale, Christopher John Northfield, Christophe Fromont
Abstract: The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount is from about one to about three daily doses of the compound and the dose is from about 0.2 mg to about 0.5 mg.
Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
June 11, 2008
Date of Patent:
May 19, 2009
Assignee:
Theravance, Inc.
Inventors:
Seok-Ki Choi, Paul Fatheree, Adam A Goldblum, Lan Jiang, Daniel D Long, Daniel Marquess, S. Derek Turner
Abstract: The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a 7- to 11-membered azabicyclo ring.
Type:
Application
Filed:
November 2, 2007
Publication date:
May 7, 2009
Inventors:
Faming Jiang, Taline Khroyan, Cris M. Olsen, Willma E. Polgar, Lawrence R. Toll, Nurulain T. Zaveri
Abstract: The invention-provides 2, 3-, 4- or 5-substituted-N1-(arylsulfonyl)indole and (heteroaryl)indole compounds of the general formula (I): in which Ar, R2, R3, R4 and R5 are as defined in the specification. The compounds bind to the 5-HT6 receptor and are useful for the treatment and prophylaxis of disorders mediated by the 5-HT6 receptor, such as obesity and CNS disorders.
Type:
Grant
Filed:
February 11, 2005
Date of Patent:
April 28, 2009
Inventors:
Patrizia Caldirola, Björn M. Nilsson, Gary Johansson
Abstract: A depressant of capsaicin-sensitive sensory nerve, containing quinuclidin-3?-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a salt thereof as an active ingredient, specifically a therapeutic drug of interstitial cystitis, hypersensitive disorder of the lower urinary tract, and/or abacterial prostatitis.
Abstract: Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.
Type:
Application
Filed:
December 16, 2008
Publication date:
April 16, 2009
Inventors:
Jordi Gras Escardo, Jesus Llenas Calvo, Hamish Ryder, Pio Orviz Diaz
Abstract: A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receplors which is (3R)-1-phencthyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octanc, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.
Type:
Application
Filed:
December 16, 2008
Publication date:
April 9, 2009
Applicant:
Laboratorios Almirall, S.A.
Inventors:
Jordi Gras Escardo, Jesus Llenas Calvo, Hamish Ryder, Pio Orviz Diaz
Abstract: This invention relates to novel azabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Grant
Filed:
May 10, 2005
Date of Patent:
April 7, 2009
Assignee:
NeuroSearch A/S
Inventors:
Dan Peters, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Tino Dyhring Jørgensen, Daniel B. Timmermann
Abstract: The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.
Type:
Application
Filed:
September 30, 2008
Publication date:
April 2, 2009
Applicant:
CoMentis, Inc.
Inventors:
Jurg R. Pfister, Meenakshi S. Venkatraman, Xiaoming Zhang
Abstract: A compound having the structure set forth in Formula (I): wherein the variables Y, R1, R2, R3, R4 and R5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
Abstract: The present disclosure provides methods of treating a tumor using M3 muscarininc receptor antagonists, such as darifenacin. In some examples, the tumor expresses M3 muscarinic receptors, such as tumors associated with smoking. Also provided are compositions that can be used to practice such methods.
Type:
Application
Filed:
March 16, 2007
Publication date:
March 5, 2009
Inventors:
Eliot R. Spindel, Harmanjatinder Sekhon, Pingfang Song
Abstract: Methods of diminishing or eliminating the co-abuse of a methylphenidate drug comprising identifying a patient or patient group suspected or likely to abuse said methylphenidate drug in combination with a substance known or suspected to give rise to l-ethylphenidate or psychotropic effect when ingested in the combination and making available to said patent or patient group said methylphenidate drug substantially free of l-threo methylphenidate.
Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.